SCD-HeFT 10 Year Follow-up (SCD-HeFT10 Yr)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Seattle Institute for Cardiac Research.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
St. Jude Medical
Information provided by:
Seattle Institute for Cardiac Research
ClinicalTrials.gov Identifier:
NCT01058837
First received: January 26, 2010
Last updated: February 9, 2010
Last verified: February 2010

January 26, 2010
February 9, 2010
September 2009
August 2011   (final data collection date for primary outcome measure)
To compare 10-year mortality data on the remaining 1855 SCD-HeFT patients since the close of follow-up from October 31, 2003 in the 3 arms of the trial (ICD, placebo and amiodarone)based upon an intent-to-treat and an on-treatment analysis. [ Time Frame: Two years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01058837 on ClinicalTrials.gov Archive Site
  • To obtain outcome data in the major subgroups of SCD-HeFT: ischemic v. non-ischemic and NYHA Class II vs. Class III heart failure, and in woman and minorities. [ Time Frame: Two years ] [ Designated as safety issue: No ]
  • To obtain 10-year ICD use rates (appropriate and inappropriate therapy), complication rates, lead failure rates and replacement rates. [ Time Frame: Two Years ] [ Designated as safety issue: No ]
  • To validate or refute the observation that amiodarone increases mortality in NYHA Class III patients. [ Time Frame: Two years ] [ Designated as safety issue: No ]
  • To obtain 10-year hospitalization and major procedure data. [ Time Frame: Two years ] [ Designated as safety issue: No ]
  • To obtain 10-year quality of life data. [ Time Frame: Two years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
SCD-HeFT 10 Year Follow-up
Sudden Cardiac Death in Heart Failure Trial 10 Year Follow-up (SCD-HeFT 10 Year)

No clinical trial that has examined the role of implantable cardioverter defibrillator (ICD) therapy in the prevention of Sudden Cardiac Death (SCD) has provided outcome data for longer than a few years. The NHLBI sponsored and placebo-controlled Sudden Cardiac Death in heart Failure Trial (SCD-HeFT) conducted from 1997 to 2003 had the largest number of patients and the longest average follow-up at 45.5 months. This study changed the national reimbursement policy for ICD therapy and remains the reference point for all other ICD evaluations in patients with congestive heart failure from ischemic or non-ischemic systolic dysfunction. Despite the outcome, the role of ICD therapy in the management of patients with heart failure has been questioned because of four principal concerns: numbers needed to treat to save a life, lead integrity over time, the negative consequences of shock therapy, and the cost of therapy. The purpose of this trial is to track down the remaining patients for a one-time follow-up regarding key outcome data.

Long-term outcome data for implantable cardioverter defibrillator (ICD) therapy is sorely needed. We will acquire these data by re-approaching the patient population from the original Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).[Bardy 2005] This research is supported by the National Heart Lung and Blood Institute of the National Institutes of Health.

SCD-HeFT was originally conducted from 1997 to 2003. It demonstrated unequivocally that ICD's save lives in patients with heart failure compared to placebo or amiodarone. More than 26 peer-reviewed publications, including three NEJM papers, have resulted from this work.[Bardy 2005, Poole 2008, Mark 2008] Despite the quality of SCD-HeFT and the evidence of the life-saving ability of ICD therapy, the role of ICD therapy in the management of patients with heart failure continues to be questioned. This study will provide long-term follow-up of the SCD-HeFT patients, which will now exceed 10 years on average.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

At the close of follow-up of the original SCD-HeFT study on October 31, 2003 there were a total of 666 deaths out of the enrollment population of 2521 patients. The American Recovery and Reinvestment Act (ARRA) of 2009 offers a perfect opportunity to do a one-time survey of the remaining 1855 patients from our last follow-up of October 31, 2003. Data on this population would allow us to obtain 10 year ICD follow-up data on the most detailed and largest ICD study ever done.

  • Left Ventricular Systolic Dysfunction
  • Congestive Heart Failure
  • Ischemic and Non-ischemic Cardiomyopathy
  • Sudden Cardiac Death Primary Prevention
Not Provided
Not Provided
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1855
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

This is a one time follow-up on patients previously enrolled. -

Exclusion Criteria:

This is a one time follow-up on patients previously enrolled.

-

Both
18 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01058837
1RC1HL100625
No
Gust H. Bardy, MD; Principal Investigator, Seattle Institute for Cardiac Research
Seattle Institute for Cardiac Research
  • National Institutes of Health (NIH)
  • St. Jude Medical
Principal Investigator: Gust H. Bardy, MD Seattle Institute for Cardiac Research
Seattle Institute for Cardiac Research
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP